Amycretin Explained: The Investigational Amylin-Plus-GLP-1 Candidate
Amycretin is an experimental Novo Nordisk drug that acts on both the GLP-1 and amylin receptors in a single molecule; it is not FDA-approved, it is not for sale, and here is what the early trials actually show.
If you follow obesity medicine even loosely, you have probably started seeing a new name in the headlines: amycretin. The numbers attached to it are eye-catching, and that is exactly why it is worth slowing down. Amycretin is real and genuinely interesting, but it is also investigational, which means you cannot buy it, your doctor cannot prescribe it, and no legitimate clinic can hand it to you today. Here is what it actually is, what the early studies have shown, and what that does and does not mean for you right now.
What is amycretin?
Amycretin is an experimental medication being developed by Novo Nordisk for adults with overweight or obesity and for people with type 2 diabetes. What makes it stand out is its design. It is a first-in-class unimolecular agonist, which is a technical way of saying that a single molecule activates two different hormone receptors at once: the GLP-1 receptor and the amylin receptor. GLP-1 is the pathway you already know from today's weight-loss injections. Amylin is a second appetite-regulating hormone that works alongside insulin. The idea is that hitting both targets with one long-acting molecule could quiet appetite and food noise more than acting on GLP-1 alone. That is an idea the trials are built to test, not a settled fact.
How is amycretin different from CagriSema?
This trips a lot of people up, because both drugs involve amylin and GLP-1. The difference is structural. CagriSema is a fixed combination of two separate peptides, cagrilintide (an amylin analog) and semaglutide (a GLP-1 medicine), co-formulated into one weekly injection. Amycretin does the same double job with a single engineered molecule instead of two. Neither approach is automatically the winner, and it is far too early to declare one. If you want the companion piece, we cover the two-peptide approach in our CagriSema explainer. The short version: amycretin is one molecule, CagriSema is two, and both are still being studied.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialThere are two versions: a shot and a pill
Amycretin is being tested in two forms at the same time: a once-weekly injection under the skin and a once-daily tablet. A convenient oral option is a big deal for a lot of people, and it is one reason amycretin draws so much attention. If the idea of swallowing a pill instead of using a needle is what pulls you in, it is worth reading our honest take on whether to wait for GLP-1 pills before you pin your plans on any single future product. In June 2025, Novo Nordisk said that, based on regulatory feedback at the end of phase 2, it would move both versions into phase 3, the large confirmatory stage, which it planned to begin in early 2026.
What have the early trials shown?
The headline numbers are large, and every one of them comes with a caveat you should read. In a phase 1b/2a study of roughly 125 adults with overweight or obesity, the once-weekly injectable form produced body-weight reductions of up to 24.3% over as long as 36 weeks, compared with 1.1% for placebo, with no weight-loss plateau seen by the end of the trial; those results were published in The Lancet. A separate phase 1 study of 144 adults tested the oral form for 12 weeks and reported mean weight loss of about 13.1% at the highest dose studied, versus 1.2% for placebo. In November 2025, a phase 2 trial in 448 people with type 2 diabetes that was not well controlled on metformin reported weight loss of up to 14.5% with the injectable form versus 2.6% for placebo, and blood-sugar (HbA1c) reductions of up to 1.5 points with the oral form by week 36.
Read those figures the way a careful clinician does. They come from early-phase trials with small numbers of participants and short follow-up. The dose amounts were dose-finding experiments, not recommendations, so no number here is a starting point for anyone. And there is a well-known pattern in drug development: striking results in small early studies often shrink once a drug is tested in thousands of people over a longer time. Phase 3 exists precisely to find out whether the early promise holds up. Until then, treat the numbers as encouraging signals, not guarantees.
What about side effects?
So far, the most common side effects reported across the amycretin studies have been gastrointestinal, mainly nausea and vomiting, along with reduced appetite. Most were described as mild to moderate. If that sounds familiar, it should: it is the same general pattern seen across the GLP-1 and amylin drug class, including medications already in use today. How well a person tolerates any of these drugs depends a lot on how carefully the dose is handled, which is one more reason this belongs in a supervised trial now and, eventually, in the hands of a physician, not a home experiment.
Is amycretin FDA-approved, and when could it arrive?
No. Amycretin is not approved by the FDA or any other regulator, for weight loss, for diabetes, or for anything else. Right now it exists only inside Novo Nordisk's own clinical trials. It is not for sale, and it is not something a pharmacy or clinic can legally provide. As for timing, you will see the year 2030 thrown around, so it is worth being precise about where that comes from. An independent industry analyst has projected possible US availability no earlier than roughly the end of 2030, with Europe perhaps a few months later, and only if the phase 3 trials succeed. That is an outside estimate, not a promise from the company and not a decision by the FDA, and drug timelines slip all the time. For the bigger picture of what is moving through the pipeline, see our overview of the next wave of weight-loss drugs.
Why you should never buy "amycretin" online
Here is the part that matters most for your safety. Because amycretin is investigational, the only legitimate way anyone receives it is by enrolling in a supervised clinical trial. So if a website offers to sell you "amycretin," a "research peptide" version, or anything marketed under a clever code name, that product is not the studied compound and not a real medicine. Its identity, dose, purity, and sterility are unverified, it is not made for human use, and injecting it is genuinely dangerous. This is the same warning we give about retatrutide and other pipeline drugs: an unapproved drug for sale online is a red flag, not a head start. No honest, physician-led clinic will sell it to you, and we will not either.
What you can actually do today
It is completely reasonable to be excited about amycretin and still want help now. The good news is that effective, physician-supervised care already exists. At New Hope Weight Loss, after a one-time $119 medical review with Dr. Anjmun Sharma, MD, eligible patients can start compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial if you would rather test the waters first. These compounded medications are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality; results vary from person to person, and your physician confirms whether they are appropriate for you. Care is offered in person in Orange County and by telehealth across California.
Amycretin may well earn its headlines someday. But someday is not today, and the smart move is not to wait on a drug that is years away and cannot be bought. The smart move is to start with real, supervised care, keep an eye on the science, and let genuinely new options prove themselves before you count on them.
Frequently asked questions
Is amycretin FDA-approved or something I can buy right now?
No. Amycretin is investigational. It is not FDA-approved, it is not sold by any pharmacy or clinic, and it is not offered at New Hope Weight Loss. The only legitimate way to receive it is by enrolling in the manufacturer's clinical trials. Any website selling "amycretin" or a "research peptide" version is offering an unapproved, unverified product that is unsafe and not something a licensed clinic will provide.
How is amycretin different from CagriSema?
They both involve the amylin and GLP-1 pathways, but the structure is different. CagriSema is a fixed combination of two separate peptides, cagrilintide and semaglutide, co-formulated into one weekly injection. Amycretin is a single engineered molecule that activates both receptors on its own. One is two drugs in one shot; the other is one drug doing both jobs. Both are still being studied.
How much weight did people lose on amycretin in the trials?
Early studies reported large figures, but they need context. A phase 1b/2a trial of roughly 125 adults reported up to 24.3% weight loss with the injectable form over 36 weeks versus 1.1% for placebo, and a 12-week phase 1 study of 144 adults reported about 13.1% with the oral form versus 1.2% for placebo. These are small, short, early-phase results that may shrink in the larger phase 3 trials, so treat them as signals rather than promises.
When will amycretin be available?
There is no confirmed date. Novo Nordisk moved both the injectable and oral forms into phase 3, the large confirmatory stage. Based on an independent industry analyst's projection, US availability would come no earlier than roughly the end of 2030, and only if those trials succeed. That is an outside estimate, not a company promise or an FDA decision, and timelines like this often slip. Anyone selling it or taking deposits today is not credible.
What can I take for weight loss right now instead of waiting?
Today, eligible patients can start physician-supervised compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month after a one-time $119 medical review with Dr. Anjmun Sharma, MD, with a $199 one-month Skeptics' Trial option. These compounded medications are not FDA-approved or brand-identical, results vary by individual, and your physician confirms whether they are appropriate for you.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.